GNLX Genelux Corporation
Genelux Corporation (GNLX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 12% planned / 88% discretionary
Largest single sale: $91.9K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Zindrick Thomas | President and CEO | Sell | 34,463 | $2.67 | $91.9K | 1,226,427 −2.7% of holding | |
| Cappello Joseph | Chief Technical Officer | Sell | 10,257 | $2.74 | $28.1K | 318,480 −3.1% of holding | |
| Yu Yong | Chief Scientific Officer | Sell | 9,683 | $2.75 | $26.7K | 258,688 −3.6% of holding | |
| Zindrick Thomas | President and CEO | Sell | 3,023 | $2.95 | $8.9K | 1,260,890 −0.2% of holding | |
| Cappello Joseph | Chief Technical Officer | Sell | 653 | $2.95 | $1.9K | 328,737 −0.2% of holding | |
| Yu Yong | Chief Scientific Officer | Sell | 653 | $2.94 | $1.9K | 268,371 −0.2% of holding | |
| Smither John W | Director | Sell | 12,000 | $2.91 | $34.9K | 91,403 −11.6% of holding | |
| Smalling Ralph | Head of Regulatory | Sell | 192 | $2.93 | $563 | 67,611 −0.3% of holding | |
| Thomas John | Director | Sell 10b5-1 | 10,000 | $2.98 | $29.8K | 472,784 −2.1% of holding | |
| Zindrick Thomas | President and CEO | Sell | 2,798 | $2.94 | $8.2K | 532,051 −0.5% of holding | |
| Cappello Joseph | Chief Technical Officer | Sell | 605 | $2.97 | $1.8K | 154,549 −0.4% of holding | |
| Yu Yong | Chief Scientific Officer | Sell | 605 | $2.97 | $1.8K | 149,706 −0.4% of holding | |
| Smalling Ralph | Head of Regulatory | Sell | 270 | $2.98 | $804 | 67,803 −0.4% of holding | |
| Smalling Ralph | Head of Regulatory | Sell | 240 | $2.51 | $602 | 68,073 −0.4% of holding | |
| Zindrick Thomas | President and CEO | Sell | 3,582 | $2.42 | $8.7K | 534,849 −0.7% of holding | |
| Cappello Joseph | Chief Technical Officer | Sell | 906 | $2.42 | $2.2K | 155,154 −0.6% of holding | |
| Yu Yong | SVP, Clinical Development | Sell | 906 | $2.42 | $2.2K | 144,938 −0.6% of holding | |
| Smalling Ralph | Head of Regulatory | Sell | 345 | $2.42 | $835 | 68,313 −0.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.